Net Service Revenue 1 Ergomed plc Annual Report and Accounts 2017
 identification and evaluation of risks – the Group employs Executive Directors and senior management with the appropriate 
 risk register – senior management works with the Audit and Risk Committee to identify key risks facing the Group, any 
 financial information – the Group prepares detailed budgets and working capital forecasts annually.
 monitoring – the Board monitors the activities of the Group through the supply of reports from various areas of the business 
 financial position and prospects memorandum – senior management works with the Audit and Risk Committee to produce 
consideration of the Company and Group current resources and working capital forecasts, the Directors have a reasonable 
The Directors present their report and financial statements for the Company and Group for the year ended 31 December 2017.
Company law requires the Directors to prepare Group and Company financial statements for each financial 
and the Company and the financial performance of the Group.
In preparing each of the Group and Company financial statements, the Directors are required to:
the assets, liabilities, financial position and profit or loss of the Company and the undertakings included in the consolidation 
 the Annual Report and financial statements, taken as a whole, are fair, balanced and understandable and provide information 
 the financial statements give a true and fair view of the state of the Group’s and of the parent company’s affairs as at 
 the Group financial statements have been properly prepared in accordance with International Financial Reporting 
 the financial statements have been prepared in accordance with the requirements of the Companies Act 2006.
We have audited the financial statements of Ergomed plc (the ‘parent company’) and its subsidiaries (the ‘Group’) which 
Materiality The materiality that we used for the Group financial statements was £595,300 which was 
In preparing the financial statements, the directors are responsible for assessing the Group’s and the parent company’s ability 
 the information given in the strategic report and the directors’ report for the financial year for which the financial statements 
 the parent company financial statements are not in agreement with the accounting 
Total comprehensive (loss)/income for the year (3,885) 610 40 Ergomed plc Annual Report and Accounts 2017
The Group financial statements were authorised for issue by the Board of Directors on 14 May 2018.
Acquisition of shares for non-cash consideration (54) – (54)
Cash and cash equivalents at end of year 4,424 – 4,424 52 Ergomed plc Annual Report and Accounts 2017
Total equity 12,422 – 12,422 54 Ergomed plc Annual Report and Accounts 2017
Acquisition of shares for non-cash consideration (54) – (54)
The pension costs charged in the financial statements represent the contributions payable by the Company during the year in 
The Group operates an equity-settled share-based option scheme under which the Group receives services from employees in 
Under IFRS 2, where such share options relate to employees of group companies other than the Company, a charge arises.
Some of the Group’s assets and liabilities are measured at fair value for financial reporting purposes.
value of an asset or a liability, the Group uses market-observable data to the extent it is available, and management estimates 
This charge is based on the fair value of such share options for financial reporting purposes.
The provision of clinical research services includes the revenues of PSR following its acquisition by the Company on 2 October 
the Board, and forecasts cash flows for the following five years based on a terminal growth rate of 2%, except for the Ergomed 
The Ergomed Group consists of a parent company, Ergomed plc, incorporated in the UK, and a number of subsidiaries held 
The Company has direct interests in the following subsidiaries which are included in the consolidated financial statements:
On 22 July 2014, the Group invested £40,000 for a 50% holding in a joint venture in Saudi Arabia – ‘Ergomed Saudi Limited’.
At 31 December 2017 – 1,613 1,613 – 678 678 74 Ergomed plc Annual Report and Accounts 2017
Amounts receivable from Group companies – – 6,714 3,963
Amounts payable to Group companies – – 7,163 3,502
The carrying amount of the Group and Company’s trade and other payables approximates to their fair value at the balance 
ii) Unapproved options can be granted to any employee (including an Executive Director) of a Group company.
income statement of £550,000 related to equity-settled share-based payment transactions in the year ended 31 December 
income statement of £nil related to equity-settled share-based payment transactions in the year ended 31 December 2017 
income statement of £175,000 related to equity-settled share-based payment transactions in the year ended 31 December 2017 
The Company’s financial assets held for managing liquidity risk, being loans and receivables, which are considered to be readily 
– – 9,616 1,957 9,804 6 21,383 21,383 84 Ergomed plc Annual Report and Accounts 2017
Amounts receivable from Group companies – 6,714 – – – 6,714 6,714
Amounts receivable from Group companies – 3,963 – – 3,963 3,963
Amounts payable to Group companies – – 3,502 – 3,502 3,502
The Group’s financial assets held for managing liquidity risk, being loans and receivables, are considered to be readily saleable 
The Group’s Finance function provides services to the business, monitors and manages the financial risks relating to the operations of 
The Group and the Company has no significant long term financial liabilities.
1,107 – 1,107 88 Ergomed plc Annual Report and Accounts 2017
On 2 October 2017, Ergomed plc acquired 100% of the issued share capital of PSR Group BV, a full service specialist orphan 
PSR contributed revenues of £977,000 and profit before tax of £38,000 to the results of the group for the year.
the acquisition of PSR had been completed on the first day of the financial year, group revenues for the year ended 
During the year the Company and its subsidiaries were charged £266,000 (2016: £240,000) by Ergomed 
the year, the Company was charged consultancy fees of £15,000 (2016: £52,000) in relation to the services of Rolf Stahel, 